{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:19Z","timestamp":1791608179398,"version":"4.3.4"},"reference-count":0,"publisher":"Press of International Journal of Ophthalmology (IJO Press)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Ophthalmol"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>AIM: To evaluate the efficacy, timing of retreatment and safety of dexamethasone (DEX) implant on macular edema (ME) secondary to diabetic retinopathy (DME) and retinal vein occlusion (RVO-ME) patients who were refractory to anti-vascular endothelial growth factor (VEGF) treatment.\nMETHODS: This retrospective study included 37 eyes received at least one DEX implant treatment for DME or RVO-ME between January 1, 2019, and January 1, 2023. These refractory DME and RVO-ME cases received at least 5 anti-VEGF injections and failure to gain more than 5 letters or a significant reduction in central retinal thickness (CRT). The best corrected visual acuity (BCVA) and CRT were measured at baseline, and at 1, 3, 4 and 6mo post-DEX implant injection. Adverse events such as elevated intraocular pressure (IOP) and cataract were recorded.\nRESULTS: For RVO cases (n=22), there was a significant increase in BCVA from 0.27\u00b10.19 to 0.35\u00b10.20 at 6mo post-DEX injection (P&lt;0.05) and CRT decreased from 472.1\u00b190.6 to 240.5\u00b139.0 \u00b5m at 6mo (P&lt;0.0001). DME cases (n=15) experienced an improvement in BCVA from 0.26\u00b10.15 to 0.43\u00b10.20 at 6mo post-DEX implant injection (P=0.0098), with CRT reducing from 445.7\u00b155.7 to 271.7\u00b134.1 \u00b5m at 6mo (P&lt;0.0001). Elevated IOP occurred in 45.9% of patients but was well-controlled with topical medications. No cases of cataract or other adverse events were reported.\nCONCLUSION: DEX implants effectively improve BCVA and reduce CRT in refractory DME and RVO-ME. Further research with larger cohorts and longer follow-up periods is needed to confirm these findings and assess long-term outcomes.<\/jats:p>","DOI":"10.18240\/ijo.2024.10.09","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T06:53:24Z","timestamp":1726642404000},"page":"1837-1842","source":"Crossref","is-referenced-by-count":4,"title":["Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion"],"prefix":"10.18240","volume":"17","author":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing 400016, China","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing 400016, China","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing 400016, China","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing 400016, China","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7543","container-title":["International Journal of Ophthalmology"],"original-title":[],"link":[{"URL":"http:\/\/ies.ijo.cn\/en_publish\/2024\/10\/20241009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T06:53:30Z","timestamp":1726642410000},"score":1,"resource":{"primary":{"URL":"http:\/\/ies.ijo.cn\/gjyken\/ch\/reader\/view_abstract.aspx?file_no=20241009&flag=1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,18]]}},"URL":"https:\/\/doi.org\/10.18240\/ijo.2024.10.09","relation":{},"ISSN":["2222-3959","2227-4898"],"issn-type":[{"value":"2222-3959","type":"print"},{"value":"2227-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}